When the FDA labeled ulipristal acetate (UPA; Ella is the product sold in the United States by HRA Pharma) an “emergency contraceptive,” Catholic and pro-life leaders criticized the decision, identified Ella as an abortifacient, and agreed it should not be used by Catholic institutions and providers.1 Ron Hamel, senior ethicist for the Catholic Health Association, shared this conclusion. In 2014, however, Hamel ended a review article by stating, “If, however, the consensus is correct, then there would seem to be sufficient moral certitude at this time to make use of UPA in Catholic hospitals.” Below I question whether a relevant consensus exists and argue that the scientific evidence militates against, rather than in favor of, use of UPA/Ella by Catholic providers.